Asymchem Laboratories Surges Over 7% on Robust Emerging Business Performance and Institutional Confidence in Long-Term Growth

Stock News14:56

Asymchem Laboratories (06821) rose more than 7%, with the stock up 7.85% to HK$99.65 at the time of reporting, generating a turnover of HK$72.12 million.

The company's first-quarter results showed revenue of RMB 1.802 billion, a year-on-year increase of 16.91%. Adjusted net profit attributable to shareholders reached RMB 423 million, up 27.91% year-on-year.

Breaking down by business segment, first-quarter revenue from small-molecule CDMO services was RMB 1.2 billion, a slight increase of 0.43% year-on-year, or 3.26% growth at constant exchange rates. Revenue from emerging businesses surged to RMB 598 million, a significant 74.07% year-on-year increase, primarily driven by strong growth in the chemical macromolecule and biological macromolecule segments.

Analysts noted that despite challenges from currency fluctuations and a high comparison base for the small-molecule business, the company delivered a robust and better-than-expected profit growth in the first fiscal quarter of 2026. This performance reflects sustained high demand for orders in its emerging businesses and improved operational efficiency. The expansion of late-stage order volumes in high-growth sectors and proactive strategic investments are expected to underpin strong certainty for long-term, high-level growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196449229?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 14:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196449229","market":"sh","top_or_hot":-1,"title":"Asymchem Laboratories Surges Over 7% on Robust Emerging Business Performance and Institutional Confidence in Long-Term Growth","media":"Stock News","content":"<p>Asymchem Laboratories (06821) rose more than 7%, with the stock up 7.85% to HK$99.65 at the time of reporting, generating a turnover of HK$72.12 million.</p>\n<p>The company's first-quarter results showed revenue of RMB 1.802 billion, a year-on-year increase of 16.91%. Adjusted net profit attributable to shareholders reached RMB 423 million, up 27.91% year-on-year.</p>\n<p>Breaking down by business segment, first-quarter revenue from small-molecule CDMO services was RMB 1.2 billion, a slight increase of 0.43% year-on-year, or 3.26% growth at constant exchange rates. Revenue from emerging businesses surged to RMB 598 million, a significant 74.07% year-on-year increase, primarily driven by strong growth in the chemical macromolecule and biological macromolecule segments.</p>\n<p>Analysts noted that despite challenges from currency fluctuations and a high comparison base for the small-molecule business, the company delivered a robust and better-than-expected profit growth in the first fiscal quarter of 2026. This performance reflects sustained high demand for orders in its emerging businesses and improved operational efficiency. The expansion of late-stage order volumes in high-growth sectors and proactive strategic investments are expected to underpin strong certainty for long-term, high-level growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Asymchem Laboratories Surges Over 7% on Robust Emerging Business Performance and Institutional Confidence in Long-Term Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAsymchem Laboratories Surges Over 7% on Robust Emerging Business Performance and Institutional Confidence in Long-Term Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-21 14:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Asymchem Laboratories (06821) rose more than 7%, with the stock up 7.85% to HK$99.65 at the time of reporting, generating a turnover of HK$72.12 million.</p>\n<p>The company's first-quarter results showed revenue of RMB 1.802 billion, a year-on-year increase of 16.91%. Adjusted net profit attributable to shareholders reached RMB 423 million, up 27.91% year-on-year.</p>\n<p>Breaking down by business segment, first-quarter revenue from small-molecule CDMO services was RMB 1.2 billion, a slight increase of 0.43% year-on-year, or 3.26% growth at constant exchange rates. Revenue from emerging businesses surged to RMB 598 million, a significant 74.07% year-on-year increase, primarily driven by strong growth in the chemical macromolecule and biological macromolecule segments.</p>\n<p>Analysts noted that despite challenges from currency fluctuations and a high comparison base for the small-molecule business, the company delivered a robust and better-than-expected profit growth in the first fiscal quarter of 2026. This performance reflects sustained high demand for orders in its emerging businesses and improved operational efficiency. The expansion of late-stage order volumes in high-growth sectors and proactive strategic investments are expected to underpin strong certainty for long-term, high-level growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1196449229","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196449229","pubTimestamp":1779346581,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Asymchem Laboratories (06821) rose more than 7%, with the stock up 7.85% to HK$99.65 at the time of reporting, generating a turnover of HK$72.12 million. The company's first-quarter results showed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0239":"医药制造","VXUS":"国际股票ETF-Vanguard","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0132":"高送转概念","BK1191":"制药","BK4588":"碎股","BK4585":"ETF&股票定投概念","06821":"凯莱英","002821":"凯莱英"},"translate_title":"凯莱英制药股价飙升逾7%，得益于强劲的新兴业务表现和机构对长期增长的信心","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"002821":1,"06821":1},"content_text":"Asymchem Laboratories (06821) rose more than 7%, with the stock up 7.85% to HK$99.65 at the time of reporting, generating a turnover of HK$72.12 million.\nThe company's first-quarter results showed revenue of RMB 1.802 billion, a year-on-year increase of 16.91%. Adjusted net profit attributable to shareholders reached RMB 423 million, up 27.91% year-on-year.\nBreaking down by business segment, first-quarter revenue from small-molecule CDMO services was RMB 1.2 billion, a slight increase of 0.43% year-on-year, or 3.26% growth at constant exchange rates. Revenue from emerging businesses surged to RMB 598 million, a significant 74.07% year-on-year increase, primarily driven by strong growth in the chemical macromolecule and biological macromolecule segments.\nAnalysts noted that despite challenges from currency fluctuations and a high comparison base for the small-molecule business, the company delivered a robust and better-than-expected profit growth in the first fiscal quarter of 2026. This performance reflects sustained high demand for orders in its emerging businesses and improved operational efficiency. The expansion of late-stage order volumes in high-growth sectors and proactive strategic investments are expected to underpin strong certainty for long-term, high-level growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196449229","isCrawlerRequest":true}